Dietary coconut oil ameliorates skin contact hypersensitivity through mead acid production in mice.


Journal

Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028

Informations de publication

Date de publication:
08 2019
Historique:
received: 22 06 2018
revised: 19 12 2018
accepted: 13 01 2019
pubmed: 8 3 2019
medline: 30 7 2020
entrez: 8 3 2019
Statut: ppublish

Résumé

Coconut oil is used as a dietary oil worldwide, and its healthy effects are recognized by the fact that coconut oil is easy to digest, helps in weight management, increases healthy cholesterol, and provides instant energy. Although topical application of coconut oil is known to reduce skin infection and inflammation, whether dietary coconut oil has any role in decreasing skin inflammation is unknown. In this study, we showed the impact of dietary coconut oil in allergic skin inflammation by using a mouse model of contact hypersensitivity (CHS). Mice maintained on coconut oil showed amelioration of skin inflammation and increased levels of cis-5, 8, 11-eicosatrienoic acid (mead acid) in serum. Intraperitoneal injection of mead acid inhibited CHS and reduced the number of neutrophils infiltrating to the skin. Detailed mechanistic studies unveiled that mead acid inhibited the directional migration of neutrophils by inhibiting the filamentous actin polymerization and leukotriene B

Identifiants

pubmed: 30843234
doi: 10.1111/all.13762
doi:

Substances chimiques

Actins 0
Biomarkers 0
Dietary Fats, Unsaturated 0
Leukotriene B4 1HGW4DR56D
8,11,14-Eicosatrienoic Acid FC398RK06S
mead acid JQS194YH3X
Coconut Oil Q9L0O73W7L

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1522-1532

Subventions

Organisme : Tokyo Biochemical Research Foundation
Pays : International
Organisme : Takeda Science Foundation
Pays : International

Informations de copyright

© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Auteurs

Prabha Tiwari (P)

Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Osaka, Japan.

Takahiro Nagatake (T)

Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Osaka, Japan.

So-Ichiro Hirata (SI)

Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Osaka, Japan.
Department of Microbiology and Immunology, Kobe University Graduate School of Medicine, Kobe-city, Hyogo, Japan.

Kento Sawane (K)

Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Osaka, Japan.
Graduate School of Pharmaceutical Sciences, Osaka University, Suita-city, Osaka, Japan.
Innovation Center, Nippon Flour Mills Co., Ltd, Atsugi-city, Kanagawa, Japan.

Azusa Saika (A)

Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Osaka, Japan.
Graduate School of Pharmaceutical Sciences, Osaka University, Suita-city, Osaka, Japan.

Yuki Shibata (Y)

Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Osaka, Japan.
Graduate School of Pharmaceutical Sciences, Osaka University, Suita-city, Osaka, Japan.

Sakiko Morimoto (S)

Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Osaka, Japan.

Tetsuya Honda (T)

Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto-city, Kyoto, Japan.

Jun Adachi (J)

Laboratory of Proteome Research, NIBIOHN, Ibaraki-city, Osaka, Japan.

Yuichi Abe (Y)

Laboratory of Proteome Research, NIBIOHN, Ibaraki-city, Osaka, Japan.

Junko Isoyama (J)

Laboratory of Proteome Research, NIBIOHN, Ibaraki-city, Osaka, Japan.

Takeshi Tomonaga (T)

Laboratory of Proteome Research, NIBIOHN, Ibaraki-city, Osaka, Japan.

Hiroshi Kiyono (H)

International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba-city, Chiba, Japan.
Division of Gastroenterology, Department of Medicine, University of California, San Diego (UCSD), San Diego, California.
CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines (cMAV), UCSD, San Diego, California.

Kenji Kabashima (K)

Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto-city, Kyoto, Japan.

Jun Kunisawa (J)

Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Osaka, Japan.
Department of Microbiology and Immunology, Kobe University Graduate School of Medicine, Kobe-city, Hyogo, Japan.
Graduate School of Pharmaceutical Sciences, Osaka University, Suita-city, Osaka, Japan.
International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
Graduate School of Medicine and Graduate School of Dentistry, Osaka University, Suita-city, Osaka, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH